A phase III randomized study by the Southwest Oncology Group in SCLC patients showed that the combination of CCRT with granulocyte−macrophage colony-stimulating factor (GM-CSF) significantly increased the incidence of toxic events, and the median survival duration was slightly shorter in GM-CSF-treated patients [4]. Here, CSF2 is linked to small cell lung carcinoma.